Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06795048 · ClinicalTrials.gov registry record · Phase 4

A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

A Phase 4 study of Neovascular Age-related Macular Degeneration (nAMD), sponsored by Hoffmann-La Roche.

Active
Registry status
Phase 4
Development phase
274
Enrollment target
20
Study locations

NCT06795048: Active Phase 4 study of Neovascular Age-related Macular Degeneration (nAMD), sponsored by Hoffmann-La Roche.

NCT06795048 is a Phase 4 study of Neovascular Age-related Macular Degeneration (nAMD) that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 274 participants, above the 178-participant average among 9 other Neovascular Age-related Macular Degeneration (nAMD) trials with a reported enrollment target (54% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06795048, a Phase 4 study of Neovascular Age-related Macular Degeneration (nAMD), is active but no longer recruiting, sponsored by Hoffmann-La Roche.

ACTIVE NOT RECRUITING
Registry status
Phase 4
Development phase
274 participants
Enrollment target
20
Study locations

Study Summary

This study is a Phase IIIb/IV, multicenter, randomized, two-arm, open-label 100-week study to investigate the efficacy, safety, and durability of intravitreal 6-mg faricimab administered at up to 24-week intervals in patients with neovascular age-related macular degeneration (nAMD) that are treatment-naïve in the study eye.

Conditions Studied

Neovascular Age-related Macular Degeneration (nAMD)

Interventions

  • DRUG Faricimab

Study Locations (20)

Ontario

  • St. Joseph's Health Care - London
  • Retina Institute of Ottawa - Ottawa
  • Toronto Retina Institute - Toronto

Florida

  • Florida Retina Institute - Orlando
  • Ctr for Retina & Macular Dis - Winter Haven

Illinois

  • Retinal Vitreal Consultants - Chicago
  • University Retina and Macula Associates, PC - Lemont

New South Wales

  • Strathfield Retina Clinic - Strathfield
  • Sydney Eye Hospital - Sydney

Victoria

  • Centre For Eye Research Australia - East Melbourne
  • Retina Specialists Victoria - Rowville

California

  • Orange County Retina Medical Group - Santa Ana

Massachusetts

  • New England Retina Consultants - Springfield

Nevada

  • Sierra Eye Associates - Sparks

Trial Details

FieldValue
Enrollment Target 274 participants
Start Date 2025-03-14
Est. Completion 2027-09-16
Phase Phase 4
Hoffmann-La Roche

909 total trials

What the registry record for NCT06795048 still lists

NCT06795048 is an interventional study that assigns participants to a tested intervention. The registered 274 participants enrollment target is mid-sized for trials with a published cap, above the 178-participant average among 9 other Neovascular Age-related Macular Degeneration (nAMD) trials with a reported enrollment target (54% higher).

The record links to 1 condition, with Neovascular Age-related Macular Degeneration (nAMD) appearing as the primary indexed condition, and to 1 intervention - of which Faricimab is the first listed.

NCT06795048 names 20 study sites across 14 states, led by Ontario, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT06795048 about?

NCT06795048 is a clinical study titled "A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration". This study is a Phase IIIb/IV, multicenter, randomized, two-arm, open-label 100-week study to investigate the efficacy, safety, and durability of intravitreal 6-mg faricimab administered at up to 24-week intervals in patients with neovascular age-related macular degeneration (nAMD) that are treatmen...

What is the current status of trial NCT06795048?

This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 274 participants. The study started on 2025-03-14. Estimated completion is 2027-09-16.

What conditions does trial NCT06795048 study?

This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration (nAMD).

What interventions are being tested in trial NCT06795048?

The interventions under investigation include: Faricimab (DRUG).

Who is sponsoring clinical trial NCT06795048?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06795048 being conducted?

This trial has 20 study locations across California, Florida, Illinois, Massachusetts, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neovascular Age-related Macular Degeneration (nAMD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06795048's enrollment target sits among peer trials

274 4th of 9 higher than 6 of 9 other Neovascular Age-related Macular Degeneration (nAMD) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Neovascular Age-related Macular Degeneration (nAMD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03808922 · 274 participants · Phase 3

    Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

  • NCT04573504 · 274 participants · Phase 4

    Antibiotics for Severe Perineal Laceration to Prevent Infection Following Repair

  • NCT05289557 · 274 participants · Phase 3

    The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents

  • NCT05952583 · 274 participants

    Selective Fetal Growth Restriction in Monochorionic Twins - an International Investigation

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06795048, the US trial registry maintained by the National Library of Medicine. NCT06795048 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.